Clinical study of sufentanil combined with promethazine for patient-controlled intravenous analgesia after thoracic surgery

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100044486

Enrollment

Unknown

Registered

2021-03-23

Start date

2021-03-31

Completion date

Unknown

Last updated

2021-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative analgesia

Interventions

control group:promethazine

experimental group:sufentanil and promethazine

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: ASA I-II, aged 18-70 years, had not used any drugs related to nausea and vomiting recently. No obvious abnormality was found in liver, kidney and electrolyte before operation.

Exclusion criteria

Exclusion criteria: Before operation, there were mental disorders, mental symptoms and diabetes mellitus. Antiemetic drugs were used within 48 hours before operation. Those who had previous postoperative nausea and vomiting were not included in this observation scope.

Design outcomes

Primary

Measure	Time frame
VAS;blood pressure;heart rate;Respiratory rate;Nausea and vomiting; Respiratory depression;skin Itch;	—

Countries

China

Contacts

Public ContactMin Li

Yongchuan Hospital Affiliated to Chongqing Medical University

292214635@qq.com+86 13983257456

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026